BPC-157
BPC-157 is a synthetic 15-amino-acid fragment studied almost exclusively in rodent models of tendon, ligament, and gut healing, where it shows pro-angiogenic and tissue-protective effects; no completed human clinical trials exist, and it is not FDA-approved for any use.
BPC-157 reconstitution calculator
Open full calculator →Typical dosing
| Goal | Range | Route | Frequency |
|---|---|---|---|
| Community/research-literature reference (systemic) | 200-350 mcg | SubQ | 1-2x daily |
| Local injection near injury site (rodent-model-derived logic) | ~250 mcg | SubQ, near affected joint/tendon | 1x daily |
| Gut/GI-focused protocols reported in peptide communities | 200-500 mcg | Oral or SubQ | 1-2x daily |
| Lower-end conservative range cited in forums | 150-200 mcg | SubQ | 1x daily |
| Upper-end range seen in anecdotal/community protocols | up to 500 mcg | SubQ | 2x daily |
Ranges compiled from research literature — not a prescription.
How it works
BPC-157 ("Body Protection Compound-157") is a synthetic 15-amino-acid sequence (GEPPPGKPADDAGLV) modeled on a fragment identified in human gastric juice, where it was described as unusually stable against enzymatic degradation. It was developed and studied predominantly by a single Croatian research group (Sikiric, Seiwerth, and collaborators, University of Zagreb) starting in the 1990s-2000s, and it has never been isolated as a naturally circulating full-length human protein with confirmed physiological function outside these studies.
The best-characterized mechanism is pro-angiogenic signaling. In rat muscle and tendon healing models, BPC-157 upregulated VEGF expression and enhanced new blood vessel formation in vivo, even though the same researchers found no direct angiogenic effect when the peptide was applied to isolated endothelial cell cultures — suggesting the effect depends on the injured-tissue environment rather than a direct receptor-ligand action on single cell types (Brcic et al., 2009). Follow-on work proposed a VEGFR2-Akt-eNOS signaling cascade and, separately, showed BPC-157 activates a Src-Caveolin-1-eNOS pathway that increases nitric oxide bioavailability and produces nitric-oxide-dependent vasodilation in isolated aorta preparations (Hsieh et al., 2020). In tendon fibroblasts, BPC-157 additionally increased growth hormone receptor expression, which in turn sensitized cells to growth-hormone-driven proliferation (Chang et al., 2014).
This angiogenic/growth-factor profile is the rationale for studying BPC-157 in tendon, ligament, and myotendinous-junction injury: these tissues are relatively hypovascular and hypocellular, so accelerating local blood vessel and growth-factor signaling is mechanistically plausible for speeding repair. In parallel, because the peptide is derived from a gastric-protective fragment, the same group has tested it extensively in rat models of intestinal anastomosis healing, fistulas, and inflammatory bowel disease, generally reporting improved healing parameters and reduced local tissue damage.
The honest caveat is that essentially this entire evidence base is rodent (mostly rat) preclinical data from a small number of overlapping research groups, using surgical or chemically-induced injury models. A Phase 1 human safety/pharmacokinetics trial in 42 healthy volunteers began in 2015, but the sponsor withdrew the results submission in 2016 and no findings were ever published. No randomized controlled human trial data exist, and rodent-to-human translation for angiogenic peptides is not guaranteed — differences in vascular biology, dosing, immunogenicity, and injury physiology mean the tendon/ligament/gut healing signals seen in rats may not reproduce in people.
Side effects & safety
- In rodent studies across multiple injury models, BPC-157 has generally been reported as well tolerated over the (short) study durations used, with authors describing 'no toxicity' at the doses tested — but these are preclinical, not human safety, findings.
- No completed human clinical trials exist: the one known Phase 1 human safety/PK trial (42 volunteers, initiated 2015) never had results published, so real human tolerability and dosing data are unavailable.
- Long-term human safety is unknown, including any theoretical concern around a pro-angiogenic compound and tissue growth over extended use — this has not been studied.
- Product purity and sourcing are a material risk: BPC-157 sold online is an unregulated 'research chemical,' not a pharmaceutical-grade product, so contamination, mislabeling, and incorrect concentration are realistic possibilities.
- It is not FDA-approved for any condition and its regulatory status for compounding is unresolved (under active FDA review as of 2026), meaning legal and quality oversight are limited.
- Interactions with medications, use during pregnancy/lactation, and effects in people with cardiovascular, cancer, or clotting-related conditions are unstudied in humans — consult a licensed clinician and treat it strictly as an investigational research compound.
Research
Primary sources — PubMed.
- Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009. https://pubmed.ncbi.nlm.nih.gov/20388964/
- Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. https://pubmed.ncbi.nlm.nih.gov/20225319/
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. https://pubmed.ncbi.nlm.nih.gov/25415472/
- Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the Src-Caveolin-1-eNOS pathway. Sci Rep. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7555539/
- Vuksic T, et al. Stable gastric pentadecapeptide BPC 157 heals ileoileal anastomosis in the rat. Surg Today. 2007. https://pubmed.ncbi.nlm.nih.gov/17713731/
- Bajramagic S, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats — A Review. Pharmaceuticals (Basel). 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11357423/
- Jozwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
- U.S. FDA. Pharmacy Compounding Advisory Committee (PCAC) Briefing Document — BPC-157 nominated bulk drug substance. 2026. https://www.fda.gov/media/193343/download